First-in-human study of  SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma, reinforcing its potential as a

In the largest machine learning study of Pompe disease to date, Volv Global demonstrates that clinician-defined endpoints can be tracked and novel disease features discovered in US claims data across 3,549 patients

Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets.

LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly. LimmaTech’s self-adjuvating and multi-antigen vaccine platform addresses common bacterial infections that currently cannot be prevented Lead program focuses on Staphylococcus aureus infection

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, today announced changes to its leadership team as part of its ongoing commitment to position the company for further long-term growth. These updates reflect a thoughtful alignment of leadership to support the continued expansion of ten23’s capabilities and manuf